Reneo Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 77.39 million compared to USD 51.96 million a year ago. Basic loss per share from continuing operations was USD 2.52 compared to USD 2.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -.--% | -0.30% | +4.38% |
Mar. 28 | Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.38% | 55.81M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- RPHM Stock
- News Reneo Pharmaceuticals, Inc.
- Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023